mirikizumab
eli lilly
['lucent-2', ' miri ', 'mirikizumab', ' uc ', 'ibd']
geert d'haens: efficacy &amp; safety of mirikizumab as maintenance therapy uc (p-iii lucent-2 study). apparent long carry-over effect of miri (class-effect?)
endoscopic/histological endpoints met
high rates of sfcr
#uegweek22 #ibd 
Professor of Medicine, Gastroenterologist, specializing in the care of patients with IBD.
National representative of Germany @ https://t.co/Qr0PthTmU8 ex @Y_ECCO_IBD chair